Senzime will publish the year-end report for 2026 on February 18, 2027.
Neuromuscular monitoring is now a clinical and operational necessity, driven by guidelines and the high incidence of residual neuromuscular block without objective monitoring.
Key differences between qualitative and quantitative TOF monitoring, the five criteria for evaluating TOF devices, and comparisons of leading solutions.
Senzime is here to support you in empowering your practice. Start today by reading a blog, watching a video or a webinar.
A leading medical device company with a mission to safeguard every patient's journey, from anesthesia to recovery.
Senzime is listed on Nasdaq Main Market (SEZI) and cross traded in the US on the OTCQX list (SNZZF).